Korro Bio (NASDAQ:KRRO) Given New $115.00 Price Target at HC Wainwright

Korro Bio (NASDAQ:KRRO) had its price objective hoisted by HC Wainwright from $100.00 to $115.00 in a research note issued to investors on Friday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $95.00 target price on shares of Korro Bio in a research report on Thursday, September 19th. William Blair initiated coverage on Korro Bio in a report on Wednesday, August 14th. They issued an “outperform” rating and a $180.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $138.00.

Korro Bio Stock Up 0.0 %

Korro Bio stock opened at $80.04 on Friday. Korro Bio has a one year low of $9.15 and a one year high of $98.00. The business’s fifty day moving average is $42.25 and its 200 day moving average is $47.33.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). As a group, research analysts anticipate that Korro Bio will post -10.09 EPS for the current year.

Insider Transactions at Korro Bio

In other news, CFO Vineet Agarwal sold 10,216 shares of the company’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $78.26, for a total value of $799,504.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 16.80% of the company’s stock.

Institutional Trading of Korro Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of KRRO. Brown Brothers Harriman & Co. bought a new position in shares of Korro Bio during the 2nd quarter valued at approximately $28,000. Lynx1 Capital Management LP bought a new position in shares of Korro Bio in the second quarter worth approximately $129,000. Rhumbline Advisers purchased a new stake in shares of Korro Bio in the second quarter worth $279,000. Bank of New York Mellon Corp bought a new stake in shares of Korro Bio during the 2nd quarter valued at $649,000. Finally, Tri Locum Partners LP purchased a new position in shares of Korro Bio during the 2nd quarter valued at $2,419,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).